Verismo's CAR-T therapy designated fast-track status by FDA

SynKIR-110 aims to treat lymphoma, cholangiocarcinoma and ovarian cancer through engineered T-cells

Verismo's CAR-T therapy designated fast-track status by FDA
Ji-Hyun Lee 1
2023-04-07 10:51:40 bluesky@hankyung.com
Bio & Pharma

Verismo Therapeutics, a US affiliate of South Korean pharmaceutical firm HLB Co., has received fast-track designation from the US Food and Drug Administration (FDA) for its CAR-T therapy, SynKIR-110, according to an announcement by HLB on Thursday.

The therapy aims to treat lymphoma, cholangiocarcinoma and ovarian cancer by extracting and editing T-cells to attack cancer cells.

The fast-track system will allow for simultaneous progress in clinical development and application for approval, reducing the time required for commercialization.

SynKIR-110 was also designated as an orphan drug for lymphoma in the US last year. Phase 1 clinical trials for these therapies are currently underway.

Write to Ji-Hyun Lee at bluesky@hankyung.com
##Verismo Therapeutics HLB Car-T Synkir-110 fast-track #korea hlb verismo #hlb synklr #verismo fasttrack fda

HLB Cell develops organoid biomaterial based on human normal cells

HLB Cell develops organoid biomaterial based on human normal cells

HLB Cell, a subsidiary of HLB Life Science Co., which specializes in the development of cell therapy products, announced on April 4 that it succeeded in producing an extracellular matrix rich in human basement membrane components through normal cell culture for the first time in the world.&nbs

HLB confirms ophthalmic disease treatment in phase 3 clinical trials

HLB confirms ophthalmic disease treatment in phase 3 clinical trials

South Korea’s biomedicine startup HLB Therapeutics Co. said on Monday that its Neurotrophic Keratopathy (NK) treatment RGN-259 proved effective and safe in first phase 3 clinical trials (SEER-1).The research report, published by the International Journal of Molecular Sciences on Dec. 29,

HLB’s Rivoceranib, Hengrui's Camrelizumab approved as combination therapy in China

HLB’s Rivoceranib, Hengrui's Camrelizumab approved as combination therapy in China

South Korea's HLB Co. announced on Thursday that the combination therapy of its drug candidate rivoceranib and Jiangsu Hengrui Pharmaceuticals Co., Ltd.’s (Hengrui Pharma) immuno-oncology drug camrelizumab was approved by the National Medical Products Administration (NMPA) as a first-lin
(* comment hide *}